experiments cells recovered from non diabetic subjects were cultured with UAG, AGE or AGE+UAG (1) . Senescence was also evaluated on EPCs derived from mice. Briefly, CACs and EPCs were washed in PBS, fixed for 3 minutes at room temperature in 2% paraformaldehyde, washed, and incubated for 24 hours at 37°C with fresh SA--gal stain solution: 1 mg/ml 5-bromo-4chloro-3-indolyl -D-galactopyranoside (X-gal), 5 mM potassium ferrocyanide, 5 mM ferricyanide, 150 mM NaCl, 2 mM MgCl2, 0.01% sodium deoxycholate, and 0.02% Nonidet P-40. Senescence was expressed as the percentage of SA--gal-positive cells over a total of 100 cells, manual count at 20X magnification by 3 independent investigators.
Western Blot Analysis -Cell extracts obtained from human or mouse samples, as indicated, were processed as previously described (4, 5) . The expression of eNOS, p-eNOS, p-Akt, Akt and of the mbKitL was evaluated on adherent cells obtained from wt-, ob/ob-, and NOS3-/--derived total BM cells. The expression of p53, p21, pRb, RAGE, p-AMPK and AMPK was also evaluated on CACs and EPCs retrived and treated as indicated. In selected experiments BM cells were in vitro subjected to AG or UAG treatment. Akt inhibitor (100 nM) was used where indicated.
Silencing of Endogenous p53, Akt and p47phox by Small Interfering RNAs (siRNA) -To obtain inactivation of p53, dCACs and dEPCs, recovered from saline-infused diabetic patients were transiently transfected with the vector pSUPER retro containing p53 siRNA or a scramble p53 siRNA sequences (1.5 µg), as previously described (6), using the Lipofectamine PLUSTM reagent (Invitrogen). The pSUPER retro containing p53 siRNA and the scramble p53 siRNA were gently provided by Dr. S. Soddu. 60 hours later whole cell extracts were processed as previously describe (1) . To obtain inactivation of p47phox and Akt, cells, recovered from saline-infused diabetic patients or from ob/ob mice, were transiently transfected with siRNA for p47phox and for Akt, respectively, and with duplex siRNAs purchased by Qiagen (Valencia, CA, USA). Transfection was performed according to the vendor's instructions. 48 hours later whole cell extracts were processed. Cell viability was evaluated at the end of the experiments.
Transplantation Assay -dCACs and dEPCs were recovered from saline-or UAG-infused diabetic patients, counted and resuspended in DMEM or in 30% complete EGM-2 and EBM-2, pH 7.4 (7) , respectively. After labelling with the fluorescent dye carboxyfluorescein diacetate succinimidyl ester (CSFE, Molecular Probes), the cells were added to 250 µL Matrigel, containing IL-3 (100 ng/ml) (for CACs) or to a solution comprising 1.5 mg/mL rat tail collagen I (BD Biosciences), 100 ng/mL human fibronectin (Chemicon) and VEGF (300ng/ml) (for EPCs) (8), and injected s.c. in SCID mice (4 mice per group). After 15 days, mice were killed and plugs were recovered, and processed for immunohistochemistry. Animal procedures conformed to the Guide for Care and Use of Laboratory Resources (National Institutes of Health publication no. 93-23, revised 1985).
Immunohistochemistry (IH) and Immunofluorescence (IF) -For IH, sections from paraffinembedded blocks of plugs were collected onto poly-lysine-coated slides. Endogenous peroxidase activity was blocked with 6% H2O2 for 8 minutes at room temperature. To detect cells labelled with fluorescent dye CSFE, anti-Fluorescein/Oregon Green polyclonal antibody (Molecular Probes) was applied to slides overnight at 4°C. Horseradish peroxidase-labeled antirabbit antibody Envision polymer (DakoCytomation, Carpinteria, CA) was incubated for 30 minutes. The reaction product was developed using 3,3-diaminobenzidine. Omission of the primary antibody or substitution with an unrelated rabbit serum IgG were used as negative controls. The quantification of neo-formed vessels was expressed as the percentage ± SD of the vessel area to the total plug area, as previously described (9) . For IF, the samples were processed as previously described (8) using human HLA class I and mouse MHC II antibodies. The number of MHC II or HLA class I positive vessels was determined by counting 10 randomly selected fields in three different samples (40X magnification).
Human Mobilization Assay -The recovering of CACs and EPCs from healthy subjects and diabetic patients, infused with UAG, AG or saline for 6 hours and 12 hours, was evaluated. CACs and EPCs were characterized by FACS analysis and manual counted by 3 independent investigators. The percentage of recovering was calculated by comparing cells at 6 and 12 hours versus time 0.
Elisa and RIA Assays -SDF-1 and VEGF serum concentrations in diabetic patients and healthy subjects were measured by competitive enzyme immunoassay (ELISA), using commercially available kits (RayBiotech, Inc, Norcross, GA), according to manufacturer's instructions. IGF-1 levels were measured with a commercially available RIA kit (Nichols Institute Diagnostics, San Juan Capistrano, CA). Before assay, IGF-1 was separated from binding proteins by acid-ethanol precipitation and measured according to the manufacturer's instructions.
Mice Mobilization Assay -8 weeks-old C57BL/6J (WT), 8 weeks-old ob/ob mice and 12 weeks-old NOS3-/mice were used. WT and ob/ob mice were i.p. injected with saline or UAG or AG at the dose of 100 µg/Kg. EPCs were recovered after 12 hours, cultured in EGM-2 medium for 21 days on collagen I-coated dishes and characterized for their surface markers (fluorochromeconjugated antibodies anti-VE-cadherin was from Bioscience, San Diego, CA, anti-KDR and anti-CD31 were from BD Biosciences, Franklin Lakes, NY), and counted by 3 independent investigators. The technical ratio of EPCs was calculated by comparing the numbers of cells/ L of blood drawn from left ventricular, as described by Hoff (10) . Mobilization assay was also performed in 12 weeksold NOS3-/-mice after 12 or 72 hours of UAG (100µg/Kg) or VEGF (50ng/ml) treatment. Isolation and Culture of BM-derived Cells and Evaluation of MMP9 Activation.-Total BM cells were isolated by flushing from femurs and tibias of ob/ob, C57BL/6J wild type and NOS3-/-mice. The adherent cells from total BM were lysed and separated on 15% SDS-PAGE, immunoblotted with the indicated antibodies. For gelatin zymography, BM plasma was collected by flushing femurs and tibias with a total of 0.5 ml PBS. After spinning, supernatants were analyzed for metalloproteinase activity by gelatinolytic zymography as described (11) .
Fluocytochemistry Analysis-A 488-Alexa UAG derivative (488-UAG) was synthesised and used as a probe for UAG binding sites. The purified UAG peptide (0.5 mg) was N-amide-labelled with the succinimidil ester of Alexafluor® 488 carboxylic acid (0.07 mg), according to manufacturer's instructions (Molecular Probes, Invitrogen). UAG binding was performed on CACs growing on FNcoated coverslips for 4 days. 488-UAG binding was carried out at 4°C for 4 hours to detect UAG binding sites at the cell surface, while at 25°C for 20 minutes to verify putative receptors clustering and internalization. Before addition of 100 nM 488-UAG, CACs were always pre-incubated with the un-labelled UAG or AG (at concentrations ranging from 10 nM to 1 M) at 4°C for 10 minutes in PBS (0.006% BSA). CACs were subsequently fixed with 3% paraformaldehyde for 15 minutes at 4°C and processed for double staining with the anti-human CD45-PE antibody (1:50) and DAPI (Sigma-Aldrich). Similar experiments were performed with EPCs (data not shown).
In vitro migration assay-Migration of BM cells collected from saline-treated WT mice was performed in Boyden's chambers. Murine BM cells, passed across the filters (8-µm pore size), after addition in the lower compartment of the chambers of BM plasma collected from 12 hours saline-or UAG-injected (100µg/Kg) mice, were counted by 3 independent investigators. In selected experiments, MMP9 or sKitL neutralizing antibodies were added.
Figure S1. CAC and EPC characterization. (A) Representative FACS analysis performed on
CACs after 4 days of culture and on EPCs after 21 days of culture both isolated from salineinfused healthy donors. Similar results were obtained on cells recovered from saline-infused T2D subjects (data not shown). Red line: preimmune IgG used as negative control, black line CD45 marker, light green line CD14 marker, blue line CD34 marker, light blue line CD31 marker, dark green line Tie2 marker, purple line KDR marker and light gray line vWF marker. Panels are representative of three different experiments independently performed with comparable results. (B) CACs and EPCs, isolated and cultured as above described, were subjected to WB analysis for eNOS expression. Human umbilical vein endothelial cells (ECs) were used as positive control. 
